Lactobacillus johnsonii for relieving ulcerative colitis and application thereof
By discovering and applying Lactobacillus johnsonii NSP009, which can produce indole lactic acid, the AhR signaling pathway is activated, and the problem of limited efficacy and side effects of the treatment of ulcerative colitis in the prior art is solved, and the ulcerative colitis is achieved. Effective improvement and safe treatment effect.
Patent Information
- Application Number
- CN202410100999.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-24
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-01-24
AI Technical Summary
The prior art has problems with drug side effects and limited efficacy in the treatment of ulcerative colitis, and no Lactobacillus johnson, which can produce indole lactic acid, has been found, which affects the regulation of the intestinal metabolic microenvironment and inflammatory relief.
A strain of Lactobacillus johnsonii NSP009 was provided, which was able to produce 20.02 mmol/L indole lactic acid within 48 hours, activates the AhR signaling pathway in the colon for the treatment of ulcerative colitis.
Lactobacillus johnia NSP009 significantly improved weight loss, disease activity index and intestinal inflammation levels in mouse models of ulcerative colitis, and has the function of assisting in the treatment of ulcerative colitis without side effects, providing safe and effective intervention Strategy.
Smart Images

Figure CN118956635A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to Lactobacillus johnsonii for relieving ulcerative colitis and application thereof, belonging to the technical field of microorganisms. Background Art
[0002] Inflammatory bowel disease (IBD) is a type of chronic inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), which is mainly manifested by symptoms such as diarrhea, abdominal pain, and blood in the stool, which has a serious impact on the health and quality of life of patients. At present, aminosalicylic acids, corticosteroids, immunomodulators and biological agents are mainly used in the clinical treatment of UC, which mainly suppress the immune response to achieve inflammation relief. However, these drugs have certain limitations in the treatment of colitis and may cause a variety of side effects. Therefore, there is an urgent need to explore safe and effective intervention treatment strategies.
[0003] Studies have shown that the disorder of intestinal flora structure plays an important role in the occurrence and development of IBD. Probiotics, as a type of microorganisms that are beneficial to the human body, can regulate the intestinal microenvironment, thereby regulating host immunity and maintaining a healthy intestinal barrier function, thereby alleviating colitis-related symptoms. IBD patients usually have a reduced abundance of Lactobacillus in the intestine, accompanied by impaired activation of the aryl hydrocarbon receptor (AhR). Lactobacillus has been widely studied as a common probiotic, and the intervention of various lactobacilli has been reported to have a good improvement effect on colitis. In addition, lactobacillus has the ability to metabolize tryptophan to produce indole derivatives. Some indole derivatives can act as AhR agonists. The activation of this receptor in the host mediates the intestinal immune balance, which is of great significance for improving colitis. Indole-3-lactic acid (ILA) is an effective agonist of AhR and has been reported to activate CD4 in vitro. + CD8αα + AhR in T cells, thereby regulating immune cell differentiation and mediating inflammation resolution; in addition, it can also activate human CD4 isolated under Th17 polarization conditions + AhR of T cells promotes the production of anti-inflammatory factor IL-22. Recent studies have also reported the improvement effect of ILA on colitis and colon cancer in mice.
[0004] Therefore, changing the host intestinal metabolic microenvironment through microbial preparations is a potential intervention strategy with important research value. Indolactic acid is one of the important components of intestinal metabolites, but Lactobacillus johnsonii that can produce indolactic acid has not yet been found. Summary of the invention
[0005] In order to overcome the deficiencies of the prior art, the present invention provides a Lactobacillus johnsonii and its application in treating ulcerative colitis. The bacteria can produce a large amount of indole lactic acid, activate the AhR signaling pathway of cells in the colon, and have a good improvement effect on colitis.
[0006] The present invention provides a strain of Lactobacillus johnsonii NSP009, which was deposited in the Institute of Microbiology, Guangdong Academy of Sciences on March 8, 2023, with the deposit address being 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, and the deposit number being GDMCC No: 63248.
[0007] The Lactobacillus johnsonii NSP009 was isolated from the colon contents of DSS-induced colitis C57BL / 6 mice. The strain was sequenced and analyzed, and its 16S rDNA sequence was shown in SEQ ID NO.1. The sequence obtained by sequencing was compared with the nucleic acid sequence of Lactobacillus johnsonii in NCBI, and the result showed that the similarity with the nucleic acid sequence of Lactobacillus johnsonii was more than 99%, so it was named Lactobacillus johnsonii NSP009.
[0008] The Lactobacillus johnsonii NSP009 has the following properties: bacterial characteristics: Gram-positive rod-shaped bacteria, no spores, no flagella, the bacterial body is about 0.5-1.5μm wide and 0.5-1.5μm long. Colony characteristics: obvious colonies are formed on the culture medium, with a diameter between 0.5-1mm, a round front shape, a convex middle, neat edges, slightly white, opaque, and a moist and smooth surface. Growth characteristics: The strain is an anaerobic bacterium, the optimal growth temperature is 36℃-38℃, the optimal growth pH is 6.0-6.5, it grows well in a culture medium containing glucose, and can enter the late logarithmic period or the early stable period in 16-24h.
[0009] The present invention also provides a microbial agent, which contains the above-mentioned Lactobacillus johnsonii NSP009.
[0010] In one embodiment of the present invention, the viable count of Lactobacillus johnsonii NSP009 in the microbial agent is not less than 1×10 6 CFU / mL or 1×10 6 CFU / g.
[0011] The present invention also provides a product, wherein the product contains the above-mentioned Lactobacillus johnsonii NSP009.
[0012] In one embodiment of the present invention, the viable count of Lactobacillus johnsonii NSP009 in the product is not less than 1×10 6 CFU / mL or 1×10 6 CFU / g.
[0013] In one embodiment of the present invention, the product is food, medicine or health care product.
[0014] In one embodiment of the present invention, the food includes beverages, dairy products or other foods containing the above-mentioned Lactobacillus johnsonii NSP009.
[0015] In one embodiment of the present invention, the medicine comprises Lactobacillus johnsonii NSP009, a drug carrier and / or a pharmaceutical excipient.
[0016] In one embodiment of the present invention, the dosage form of the medicine or health product includes granules, capsules, tablets, pills or oral liquids.
[0017] In one embodiment of the present invention, the pharmaceutical excipient is a pharmaceutically acceptable excipient.
[0018] In one embodiment of the present invention, the acceptable excipients include one or more commonly used thickeners, antioxidants, acid-base regulators, emulsifiers, preservatives, fillers, binders, wetting agents, disintegrants, lubricants and flavoring agents.
[0019] In one embodiment of the present invention, the filler is starch, sucrose, lactose, calcium sulfate and / or microcrystalline cellulose.
[0020] In one embodiment of the present invention, the binder is a cellulose derivative, alginate, gelatin and / or polyvinyl pyrrolidone.
[0021] In one embodiment of the present invention, the wetting agent is water, ethanol, starch and / or syrup.
[0022] In one embodiment of the present invention, the disintegrant is sodium carboxymethyl starch, carboxypropyl cellulose, cross-linked carboxymethyl cellulose, agar, calcium carbonate and / or sodium bicarbonate.
[0023] In one embodiment of the present invention, the lubricant is talc, calcium stearate, magnesium stearate, micro powder silica gel and / or polyethylene glycol.
[0024] In one embodiment of the present invention, the flavoring agent is simple syrup, sucrose, lecithin, orange peel syrup, cherry syrup, lemon, fennel, peppermint oil, sodium alginate, gum arabic, gelatin, methylcellulose, sodium carboxymethylcellulose, citric acid, tartaric acid and / or sodium bicarbonate.
[0025] The present invention also provides the use of the above-mentioned Lactobacillus johnsonii NSP009 or the above-mentioned microbial agent in preparing a product for preventing and / or treating ulcerative colitis.
[0026] In one embodiment of the present invention, the product includes a medicine or a health product.
[0027] In one embodiment of the present invention, the viable count of Lactobacillus johnsonii NSP009 in the product is not less than 1×10 6 CFU / mL or 1×10 6 CFU / g.
[0028] In one embodiment of the present invention, the medicine comprises Lactobacillus johnsonii NSP009, a drug carrier and / or a pharmaceutical excipient.
[0029] In one embodiment of the present invention, the dosage form of the medicine or health product includes granules, capsules, tablets, pills or oral liquids.
[0030] In one embodiment of the present invention, the dosage form of the medicine or health product includes granules, capsules, tablets, pills or oral liquids.
[0031] In one embodiment of the present invention, the pharmaceutical excipient is a pharmaceutically acceptable excipient.
[0032] In one embodiment of the present invention, the acceptable excipients include one or more commonly used thickeners, antioxidants, acid-base regulators, emulsifiers, preservatives, fillers, binders, wetting agents, disintegrants, lubricants and flavoring agents.
[0033] In one embodiment of the present invention, the filler is starch, sucrose, lactose, calcium sulfate and / or microcrystalline cellulose.
[0034] In one embodiment of the present invention, the binder is a cellulose derivative, alginate, gelatin and / or polyvinyl pyrrolidone.
[0035] In one embodiment of the present invention, the wetting agent is water, ethanol, starch and / or syrup.
[0036] In one embodiment of the present invention, the disintegrant is sodium carboxymethyl starch, carboxypropyl cellulose, cross-linked carboxymethyl cellulose, agar, calcium carbonate and / or sodium bicarbonate.
[0037] In one embodiment of the present invention, the lubricant is talc, calcium stearate, magnesium stearate, micro powder silica gel and / or polyethylene glycol.
[0038] In one embodiment of the present invention, the flavoring agent is simple syrup, sucrose, lecithin, orange peel syrup, cherry syrup, lemon, fennel, peppermint oil, sodium alginate, gum arabic, gelatin, methylcellulose, sodium carboxymethylcellulose, citric acid, tartaric acid and / or sodium bicarbonate.
[0039] Beneficial Effects
[0040] 1. The Lactobacillus johnsonii NSP009 of the present invention is a strain screened from the intestinal tract of colitis mice and has a colitis-improving effect. The Lactobacillus johnsonii NSP009 has a new property of producing indole lactic acid. After fermentation for 48 hours, 20.02 mmol / L indole lactic acid can be produced, which is 1.52 times that of the standard strain.
[0041] 2. The Lactobacillus johnsonii NSP009 of the present invention also has the function of adjuvant treatment of ulcerative colitis. The results of mouse experiments showed that the strain has the ability to resist weight loss, increased disease activity index, and shortened colon caused by colitis, and effectively improves colon epithelial cell damage and significantly reduces the level of inflammation in the intestine. In addition, the strain also has the ability to produce a large amount of indole lactic acid, which can act as an agonist of AhR and promote the production of anti-inflammatory factor IL-22. This result can provide strong theoretical support for the adjuvant treatment of ulcerative colitis with probiotics.
[0042] 3. Lactobacillus johnsonii is a kind of probiotics and has been included in the "List of Bacteria that can be used in Food" issued by the Ministry of Health. Therefore, the Lactobacillus johnsonii NSP009 screened by the present invention has no side effects on the human body, can be used to prepare a pharmaceutical composition and fermented food that can relieve ulcerative colitis, and has a very broad application prospect.
[0043] Biomaterial Deposit
[0044] A strain of Lactobacillus johnsonii (Lactobacillus johnsonii) NSP009 was deposited in the Institute of Microbiology, Guangdong Academy of Sciences on March 8, 2023, with the taxonomic name: Lactobacillus johnsonii, the deposit number is GDMCCNo:63248, and the deposit address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 : Changes in body weight and disease activity index of mice with colitis during the intervention of Lactobacillus johnsonii NSP009; A is the change in body weight of mice in each group during the intervention period, and B is the change in disease activity index of mice during the intervention period.
[0046] Figure 2 : Effects of Lactobacillus johnsonii NSP009 intervention on colon length in colitis mice and representative colon images; A is a representative image of the colon of each group of mice, and B is the colon length.
[0047] Figure 3 : Effects of Lactobacillus johnsonii NSP009 on colon pathological damage in colitis mice; A is a representative section of colon tissue HE staining, and B is the colon pathological damage score.
[0048] Figure 4 :The effect of Lactobacillus johnsonii NSP009 on the level of colon inflammation in colitis mice; wherein, A is the myeloperoxidase (MPO) protein level, B is the TNF-α level, C is the IL-6 level, and D is the IL-22 level.
[0049] Figure 5 :The effect of Lactobacillus johnsonii NSP009 on the expression of colon AhR-related genes after intervention in colitis mice; where A is the gene expression level of Ahr; B is the gene expression level of Cyp1a1.
[0050] "*" indicates significant differences compared with the model group (*: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001); the data results in some tables are expressed as mean values, and the data were analyzed by one-way analysis of variance and Tukey's HSD post hoc test using SPSS24. Different letters "a, b, c, etc." in the same column represent significant differences between groups (p<0.05). DETAILED DESCRIPTION
[0051] The mice involved in the following examples were purchased from Beijing Weitong Lihua Experimental Animal Co., Ltd. and were kept in an SPF environment with constant temperature (22±2°C) and constant humidity (55±10%) to ensure a 12-h light / dark cycle. Standard diet and water were provided freely. The experiment was started after one week of adaptive feeding. The DSS (molecular weight 36,000-50,000Da) involved in the following examples were all purchased from MP Company in the United States. The MPO, TNF-α, IL-6 and IL-22EILSA kits involved in the following examples were all purchased from Nanjing Fumax Biotechnology Co., Ltd.; the BCA protein concentration determination kit involved was purchased from Shanghai Biyuntian Biotechnology Co., Ltd.; the reverse transcription kit and qPCR kit involved were all purchased from Takara Company in Japan. The culture medium components involved in the following examples were all purchased from Shanghai Yuanye Company.
[0052] The following examples relate to culture medium:
[0053] Preparation of enrichment medium (g / L): 1.0 potassium dihydrogen phosphate, 3.0 sodium bicarbonate, 9.0 potassium chloride, 9.0 sodium chloride, 1.2 anhydrous magnesium sulfate, 0.2 potassium chloride dihydrate, 0.01 ferrous sulfate heptahydrate, 1.4 acid hydrolyzed casein, 2.34 tryptone, 2.34 bacterial tryptone, 2.1 yeast extract, 1.6 cysteine hydrochloride, 0.8 bile salt, 0.1 hemin chloride, 1.0 Tween, 0.01 vitamin K1, 5.0 β-glucan, dissolved in 1L distilled water, mixed evenly, then adjusted to pH 6.2-6.9, sterilized at 115-121°C for 15-20min to obtain the enrichment medium.
[0054] MRS liquid culture medium (g / L): 10.0 peptone, 8.0 beef extract powder, 4.0 yeast extract powder, 20.0 glucose, 2.0 dipotassium hydrogen phosphate, 2.0 diammonium hydrogen citrate, 5.0 sodium acetate, 0.2 magnesium sulfate, 0.04 manganese sulfate, 1.0 Tween, dissolved in 1L distilled water, and 0.5-1g / L cysteine hydrochloride was added, mixed evenly, and then the pH was adjusted to 6.6-7.0, and sterilized at 115-121°C for 15-20min to obtain the MRS liquid culture medium.
[0055] Preparation of MRS solid culture medium: Add 1.5-2% agar to the MRS liquid culture medium, mix well, adjust the pH to 6.6-7.0, and sterilize at 115-121° C. for 15-20 minutes to obtain the MRS solid culture medium.
[0056] MRS selective medium (g / L): 10.0 peptone, 8.0 beef extract powder, 4.0 yeast extract powder, 2.0 dipotassium hydrogen phosphate, 2.0 diammonium hydrogen citrate, 5.0 sodium acetate, 0.2 magnesium sulfate, 0.04 manganese sulfate, 1.0 Tween, 5 beta-glucan, dissolved in 1L distilled water, and 0.5-1g / L cysteine hydrochloride is added, mixed evenly, and then the pH is adjusted to 6.6-7.0, and sterilized at 115-121°C for 15-20min to obtain the liquid medium.
[0057] The detection methods involved in the following embodiments are as follows:
[0058] Disease activity index evaluation: Starting from the 0th day of DSS treatment, the degree of diarrhea and bloody stools of mice were monitored daily. Combined with the changes in body weight, the daily DAI (the average of the three indicators) was calculated according to the scoring criteria in Table 1, and the DAI change curve of mice during the modeling period was plotted.
[0059] Table 1 Scoring criteria for various indicators of mouse disease activity index
[0060]
[0061] HE staining and pathological analysis of colon sections: The colon tissue was fixed in 4% paraformaldehyde solution for 24 h, then dehydrated and paraffin-embedded, and cut into 3-4 μm thick paraffin sections. HE staining was performed according to the following steps.
[0062] (1) Dewaxing of paraffin sections: Dewax the sections with xylene I for 20 min, dewax with xylene II for 20 min, soak in anhydrous ethanol I for 5 min, soak in anhydrous ethanol II for 5 min, soak in 75% alcohol for 5 min, and wash with tap water.
[0063] (2) Hematoxylin staining: Soak the sections in hematoxylin stain for 3-5 minutes, wash with tap water, turn blue with bluing solution, and rinse with running water.
[0064] (3) Eosin staining: The sections were dehydrated in 85% ethanol and 95% ethanol for 5 min, and then immersed in eosin staining solution for 5 min.
[0065] (4) Dehydration and sealing: Soak the sections in anhydrous ethanol I for 5 min, anhydrous ethanol II for 5 min, anhydrous ethanol III for 5 min, xylene I for 5 min, and xylene II for 5 min, and finally seal the sections with neutral gum.
[0066] (5) Microscope examination, image acquisition and analysis.
[0067] Tissue damage was pathologically scored according to the scoring criteria in Table 2. Histological score = epithelial damage score + inflammation degree score + lesion depth score.
[0068] Table 2 Histological injury scoring criteria
[0069]
[0070] Determination of the content of MPO and related cytokines in colon tissue: Take 30 mg of colon tissue, add sterile PBS and 2 3 mm grinding beads at a ratio of 1:9 (w / v), and use a grinder to fully grind the tissue. The resulting homogenate was centrifuged at 4°C and 10,000 rpm for 10 minutes, and the supernatant was collected for subsequent determination. The corresponding ELISA kits were used to detect the content of MPO, TNF-α, IL-6 and IL-22 in mouse colon tissue. The specific operation steps and precautions were referred to the manufacturer's instructions. In addition, the total protein concentration of the sample was determined using the BCA protein concentration determination kit, and the content of the target protein per mg of total protein was calculated.
[0071] RNA extraction and gene expression determination: Trizol reagent was used to extract total RNA from colon tissue, and reverse transcription kit was used to perform reverse transcription on total RNA from colon tissue. Using the cDNA obtained by reverse transcription as a template, TB Green Premix Ex Taq II kit (TAKARA) was used to prepare the PCR reaction system (20 μL), namely 10 μL TB Green Premix Ex Taq II (Tli RNaseH Plus), 6 μL dd H2O, 0.8 μL upstream primer, 0.8 μL downstream primer, 0.4 μL ROX Reference Dye II and 2 μL cDNA template. The primers are detailed in Table 3, where β-actin is the internal reference gene. Reaction conditions: 50°C for 2 min, 95°C for 30 s for initial denaturation; followed by 95°C for 20 s, 60°C for 30 s, and 72°C for 30 s for 40 cycles; extension at 72°C for 5 min to terminate the reaction. According to the Ct value of the target gene and the internal reference gene, 2 -△△Ct The relative expression of target genes was calculated.
[0072] Table 3 Target genes and primer sequences
[0073]
[0074] Detection and quantification of indole lactic acid: The metabolites in bacterial culture fluid and mouse colon contents were extracted by organic extraction, and the metabolites were analyzed and detected by QTRAP 4500 HPLC-MS / MS. The mass spectrometry data were imported into MultiQuant (v3.0.1), and the target substances were quantitatively analyzed according to the corresponding standard curve.
[0075] Example 1: Isolation and identification of Lactobacillus johnsonii NSP009
[0076] 1. Enrichment of fecal bacteria
[0077] The colon contents of mice 7 days after colitis modeling were collected and quickly transferred to an anaerobic incubator. An appropriate amount of sterile PBS containing 0.1% L-cysteine hydrochloride was added and vortexed to mix well. Then, the bacterial solution was passed through a 100 μm sterile cell sieve to obtain the bacterial solution. The bacterial solution was added to the enrichment medium at 2% (v / v) and cultured in an anaerobic environment at 37°C for 24 hours with shaking.
[0078] 2. Isolation and purification of Lactobacillus
[0079] Take the diluted bacterial solution and spread it on MRS solid medium, let it stand and culture for 2-3 days for selective culture of lactobacillus. Select a plate with appropriate colony number, pick single colonies with neat edges, slightly white, opaque, moist and smooth surface and consistent morphology on the solid medium, and inoculate them into 5mL liquid MRS selective medium, and culture them under anaerobic conditions at 37℃ for 24h to obtain purified culture solution.
[0080] 3. Strain preservation and identification
[0081] The bacterial culture fluid with the best activity in step 2 was used as the amplification template, and 16S universal primers (see Table 4) were used for PCR amplification. The PCR system is shown in Table 5, and amplification was performed on the PCR instrument according to the following process: pre-denaturation at 95°C for 5 minutes; then 95°C for 15 seconds, 60°C for 15 seconds, and 72°C for 45 seconds, and the cycle was repeated 29 times; extension at 72°C for 5 minutes; cooling to 4°C to terminate the reaction.
[0082] The amplified product was detected by 1% agarose electrophoresis and then sequenced. The high-quality sequences in the sequenced sequence were intercepted and submitted to NCBI for BLAST comparison to find the annotation information of the related sequences. The results showed that the sequence had a homology of more than 99% with the 16SrDNA sequence of Lactobacillus johnsonii. The strain is now named Lactobacillus johnsonii NSP009 and is preserved in the Institute of Microbiology, Guangdong Academy of Sciences.
[0083] Table 4 Primer names and sequences
[0084]
[0085] Table 5 PCR system
[0086]
[0087] 4. Determination of indole lactic acid production
[0088] The activated Lactobacillus johnsonii NSP009 and Lactobacillus johnsonii ATCC33200 were inoculated into MRS medium at an inoculum amount of 2% (v / v), and cultured anaerobically at 37°C for 48 hours. Indole lactic acid was detected by HPLC-MS / MS, and the signal intensity is shown in Table 6. The results show that the indole lactic acid production of the Lactobacillus johnsonii NSP009 of the present invention is significantly higher than that of the standard strain of Lactobacillus johnsonii ATCC33200, which is 1.52 times the production of the standard strain.
[0089] Table 6 Indole lactic acid production in bacterial culture fluid
[0090]
[0091]
[0092] Note: Different letters in the same column indicate significant differences (P<0.05).
[0093] Example 2: Effects of Lactobacillus johnsonii NSP009 on body weight and disease activity index in mice with ulcerative colitis
[0094] The specific steps are as follows:
[0095] 1. Preparation of cryopreservative of Lactobacillus johnsonii NSP009:
[0096] (1) Cultivation method: In a sterile anaerobic environment, the Lactobacillus johnsonii NSP009 strain was streaked on an MRS solid culture medium and cultured under anaerobic conditions for 48 h. After a single colony was formed, a single colony was picked and inoculated into an MRS liquid culture medium. The culture was anaerobically carried out at 37° C. for 16-24 h until a stable period was reached. The OD value at this time was 1.0-1.4, and a seed solution was prepared.
[0097] (2) Preparation of protective agent: Based on the final concentration, weigh 1 g / L cysteine hydrochloride and 200-300 g / L glycerol, evenly dissolve them in distilled water, and sterilize them at 115-121°C for 15-20 min.
[0098] (3) Preparation of cryopreservative: The Lactobacillus johnsonii NSP009 seed solution cultured to the stable phase in step (1) is centrifuged (8000 rpm, 10 min, 4° C.), washed 1-2 times with sterile phosphate buffer (pH 7.2), and then resuspended with the protective agent prepared in step (2) to obtain the Lactobacillus johnsonii NSP009 cryopreservative, which is stored at -80° C. for future use.
[0099] 2. Preparation of Lactobacillus johnsonii NSP009 bacterial agent:
[0100] (1) Activating the strain: streak the Lactobacillus johnsonii NSP009 cryopreservation agent prepared in step 1 on MRS solid medium, culture under anaerobic conditions for 48 h, and after a single colony is formed, inoculate the single bacterium into MRS liquid medium and culture anaerobically at 37° C. for 16-24 h to reach a stable period (OD value: 1.1-1.4).
[0101] (2) Preparation of bacterial agent: Take 100 μL of the culture solution obtained in step (1) with different dilution multiples and apply it to MRS solid medium, count the number of colonies on the MRS solid plate, and calculate the number of viable bacteria in the liquid medium of step (1). After washing 1-2 times with sterile phosphate buffer (pH 7.2), prepare the bacterial solution to a concentration of 1×10 9 CFU / mL of the preparation.
[0102] 3. Experimental methods:
[0103] The present invention uses a 3% (w / v) DSS aqueous solution to induce ulcerative colitis in mice. 24 6-week-old healthy male C57BL / 6J mice were randomly divided into four groups (6 mice in each group): a normal group, a DSS-induced colitis model group (referred to as the model group), Lactobacillus johnsonii NSP009+DSS (referred to as the NSP009 group), and mesalazine+DSS (referred to as the mesalazine group).
[0104] Preparation of mesalazine preparation: 30 mg of mesalazine granules (Shanghai Aifa Pharmaceutical Co., Ltd.) were dissolved in 1 mL of 5% (w / v) sodium carboxymethylcellulose aqueous solution to obtain a 30 mg / mL mesalazine preparation.
[0105] The experimental process is shown in Table 7. After one week of adaptation:
[0106] Normal group: The mice were free to drink purified water from day 0 to day 14, and were gavaged with 0.1 mL of sterile phosphate buffer every day.
[0107] Model group: The mice were allowed to drink purified water freely from day 0 to day 7, and 3% DSS solution freely from day 8 to day 14. The mice were gavaged with 0.1 mL of sterile phosphate buffer every day from day 0 to day 14.
[0108] NSP009 group: The mice were allowed to drink purified water freely from day 0 to day 7, and 3% DSS solution freely from day 8 to day 14. The mice were intragastrically gavaged with 0.1 mL of Lactobacillus johnsonii NSP009 preparation every day from day 0 to day 14.
[0109] Mesalazine group: The mice were allowed to drink purified water freely from day 0 to day 7, and 3% DSS solution freely from day 8 to day 14. The mice were intragastrically administered with 0.1 mL of mesalazine preparation every day from day 0 to day 14.
[0110] During DSS treatment, the body weight, loose stools, and bloody stools of mice were monitored at the same time every day.
[0111] Table 7 Experimental process
[0112]
[0113] 4. Experimental results:
[0114] The weight changes of mice in each group were as follows Figure 1 As shown in A. The results showed that DSS treatment could significantly reduce the body weight of mice (P<0.001), and the body weight of mice in the model group decreased to 77.74% of the initial body weight on the last day of DSS treatment. The intervention of Lactobacillus johnsonii NSP009 and mesalazine in mice could significantly reduce the weight loss of mice (on the 7th day after DSS treatment, the weight loss of mice in the NSP009 group and mesalazine group recovered to 83.58% and 83.78% of the initial body weight, respectively, P<0.001), and there was no significant difference between the two groups (P>0.05).
[0115] The changes of disease activity index in each group of mice are as follows Figure 1 B. The results showed that DSS treatment gradually increased the disease activity index, that is, increased the degree of loose stools, bloody stools and weight loss. The intervention of Lactobacillus johnsonii NSP009 and mesalazine significantly reduced the disease activity index of mice (on the 7th day after DSS treatment, the disease activity index of mice in the NSP009 group and mesalazine group recovered to 2.83 and 2.78, respectively, P<0.001), and there was no significant difference between the two groups (P>0.05).
[0116] The above results show that the Lactobacillus johnsonii NSP009 of the present invention can significantly improve the body weight and disease activity index-related colitis phenotype of mice after DSS treatment, and its effect is no different from that of the positive drug mesalazine.
[0117] Example 3: Effects of Lactobacillus johnsonii NSP009 on colon length and pathology in mice with ulcerative colitis
[0118] The specific steps are as follows:
[0119] The specific experimental method was the same as in Example 2. After the intervention ended on the 14th day, the mice were euthanized. The cecum and colon were quickly dissected and removed, the length of the colon was recorded, and the tissue was photographed and recorded. With the cecum as the proximal end and the anus as the distal end, 1 cm of the colon tissue at the distal end was taken and stored in a 4% paraformaldehyde solution.
[0120] DSS can cause atrophy of the mouse colon while causing colitis, so colon length is often used as one of the criteria for considering the severity of colitis. Figure 2 A and B show that the average colon length of the DSS group was 4.27 cm, which was 61.54% of the average colon length of the normal group. Intervention with Lactobacillus johnsonii NSP009 and mesalazine significantly improved the shortening of colon length (P<0.0001), with average lengths of 5.03 cm and 5.00 cm, respectively.
[0121] The colon tissues were stained with HE and pathologically analyzed. The representative sections and pathological scoring results of each group are shown in the figure. Figure 3 As shown in A and B. It was observed that the colon tissue structure of mice in the normal group was intact, the epithelial cells were arranged neatly, and no obvious lesions were observed; the colon tissue structure of mice in the model group was incomplete, the epithelial cells were arranged disorderly or even disappeared, the crypt structure was destroyed, the mucosa and submucosa were congested and edematous, and there was extensive inflammatory infiltration in the mucosal lamina propria and submucosa. Compared with the model group, Lactobacillus johnsonii NSP009 and mesalazine could significantly improve the pathological morphology of colon tissue, repair mucosal damage, and reduce the invasion of inflammatory cells (P<0.0001); the colon pathology score of mice in the NSP009 group was 7.83, slightly lower than that of mice in the mesalazine group (8.36).
[0122] The above results show that Lactobacillus johnsonii NSP009 can significantly improve colon atrophy in colitis mice and protect the integrity of colon tissue structure, and the effect is slightly better than that of the mesalazine group.
[0123] Example 4: Effect of Lactobacillus johnsonii NSP009 on intestinal inflammation levels in mice with ulcerative colitis
[0124] The specific steps are as follows:
[0125] The specific experimental method was the same as in Example 2. After the intervention ended on the 14th day, the mice were euthanized. The colon tissues were stored at -80°C and used for ELISA detection.
[0126] MPO is a protein produced by neutrophils and is an important marker of inflammatory response. It is widely used to reflect the inflammatory state of the intestinal mucosa. Figure 4A, The level of colonic MPO in the model group mice was significantly higher than that in the normal group (P<0.0001). Lactobacillus johnsonii NSP009 and mesalazine can significantly reduce the level of MPO in the intestine of colitis mice (P<0.0001). Compared with the model group, the MPO expression in the NSP009 group was reduced by 0.73 times, which has a certain improvement effect on inflammation.
[0127] TNF-α and IL-6 are two important cytokines that can activate inflammatory cells and cause inflammatory responses, and are therefore generally considered pro-inflammatory factors. Figure 4 B, The levels of TNF-α and IL-6 in the colon of mice in the model group were significantly higher than those in the normal group (P<0.001), but the intervention of Lactobacillus johnsonii NSP009 and mesalazine could significantly reduce their levels in the colon (P<0.01) (TNF-α concentration was normal group: 9.21pg / mg protein; model group: 62.67pg / mg protein; NSP009 group: 38.27pg / mg protein; IL-6 concentration was normal group: 40.27pg / mg protein; model group: 116.18pg / mg protein; NSP009 group: 61.94pg / mg protein). IL-22 is a cytokine with anti-inflammatory effects. Compared with the model group, Lactobacillus johnsonii NSP009 and mesalazine intervention significantly increased the level of this cytokine (P<0.05) and restored it to near normal levels (normal group: 321.12 pg / mg protein; NSP009 group: 310.67 pg / mg protein).
[0128] The above results show that the Lactobacillus johnsonii NSP009 of the present invention can significantly downregulate the inflammation level in colitis mice, reduce the level of pro-inflammatory cytokines, increase the level of anti-inflammatory cytokines, restore intestinal immune balance, and effectively control the occurrence and development of colitis.
[0129] Example 5: Effect of Lactobacillus johnsonii NSP009 on intestinal indole lactic acid levels in mice with ulcerative colitis
[0130] The specific steps are as follows:
[0131] The specific experimental method is the same as that in Example 2. After the intervention ended on the 14th day, the mice were euthanized. The colon was quickly removed, and the colon contents were stored at -80°C for the detection of indole lactic acid. The metabolites in the colon contents were extracted by 80% (v / v) methanol, and indole lactic acid was detected by HPLC-MS / MS. The concentrations are shown in Table 8. The results show that the Lactobacillus johnsonii NSP009 of the present invention can significantly increase the level of indole lactic acid in colitis mice, restoring it to a level equivalent to that of the normal group; compared with the model group, the indole lactic acid concentration increased by 1.65 times; compared with the mesalazine group, the indole lactic acid concentration increased by 1.46 times.
[0132] Table 8 Indole lactic acid concentration in mouse colon contents
[0133]
[0134] Note: Different letters in the same column indicate significant differences (P<0.05).
[0135] Example 6: Effect of Lactobacillus johnsonii NSP009 on the activation of AhR pathway in the intestine of mice with ulcerative colitis
[0136] The specific experimental method was the same as that in Example 2. After the intervention ended on the 14th day, the mice were euthanized. The colon tissue was rinsed with pre-cooled PBS, and 1 / 3 of it was soaked in RNA wait solution overnight and then frozen at -80°C for RNA extraction and qPCR experiments.
[0137] The expression of Ahr and its downstream key gene Cyp1a1 in the mouse intestine was detected by qPCR. Figure 5 As shown in A and B. The expression of Ahr and Cyp1a1 in the intestine of colitis mice was significantly decreased compared with that of the normal group (P<0.0001), which was 48.21% and 34.34% of the normal group, respectively. Lactobacillus johnsonii NSP009 could significantly upregulate the expression of these two genes (P<0.0001), and was close to the level of the normal group (the expression of Ahr and Cyp1a1 was 89.3% and 84.4% of the normal group, respectively). In addition, mesalazine had no significant effect on the expression of Ahr and Cyp1a1 (P>0.05); the activation of these two genes by Lactobacillus johnsonii NSP009 was significantly higher than that of mesalazine (P<0.001).
[0138] The above results show that the Lactobacillus johnsonii NSP009 of the present invention can significantly upregulate the expression of Ahr and Cyp1a1 in colitis mice, and effectively improve the impaired activation of the AhR signaling pathway in mice; the indole lactic acid produced by the strain may mediate the activation of the pathway.
[0139] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. A strain of Lactobacillus johnsonii NSP009 was deposited at the Institute of Microbiology, Guangdong Academy of Sciences on March 8, 2023. The deposit address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, and the deposit number is GDMCC No: 63248.
2. A microbial agent, characterized in that: Contains the Lactobacillus johnsonii according to claim 1.
3. The microbial agent according to claim 2, characterized in that In the microbial agent, the number of viable bacteria of Lactobacillus johnsonii NSP009 is not less than 1×10 6 CFU / mL or 1×10 6 CFU / g.
4. A product, characterized in that The product contains the Lactobacillus johnsonii described in claim 1.
5. The product according to claim 4, characterized in that In the product, the number of viable Lactobacillus johnsonii is not less than 1×10 6 CFU / mL or 1×10 6 CFU / g.
6. The product according to claim 4 or 5, characterized in that The product is food, medicine or health product.
7. The product according to claim 6, characterized in that The food includes beverages, dairy products or other foods containing the Lactobacillus johnsonii according to claim 1.
8. The product according to claim 6, characterized in that The medicine contains Lactobacillus johnsonii and also contains a drug carrier and / or a pharmaceutical excipient.
9. Use of the Lactobacillus johnsonii according to claim 1 or the microbial agent according to claim 2 or 3 in the preparation of a product for preventing and / or treating ulcerative colitis.
10. The product according to claim 9, characterized in that The product is a medicine or a health food.
Citation Information
Patent Citations
Lactobacillus agilis and application thereof
CN105950496A
Application of lactobacillus johnsonii in preventing and / or treating inflammatory bowel diseases
CN112121068A
Lactobacillus johnsonii SXDT-23 and application thereof
CN114806978A
Lactobacillus johnsonii producing feruloyl esterase and application of lactobacillus johnsonii in relieving ulcerative colitis
CN115992059A
Probiotic bacillus compositions and methods of use
CN116507349A
